$1.20
0.043.45%
At Close: -
$1.21
0.010.83%
After Hours: 6:03 PM EDT
15 minutes delayed
Adaptimmune Therapeutics
ADAPNASDAQ
Adaptimmune Therapeutics (NASDAQ:ADAP) Stock, Analyst Ratings, Price Targets, Forecasts
Adaptimmune Therapeutics PLC has a consensus price target of $4.56 based on the ratings of 21 analysis. The 3 most-recent analyst ratings were released by Scotiabank, Mizuho, and EF Hutton on May 30, 2024, May 17, 2024, and August 10, 2023, respectively. With an average price target of $5.38 between Scotiabank, Mizuho, and EF Hutton, there's an implied 344.90% upside for Adaptimmune Therapeutics PLC from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Scotiabank
Mizuho
EF Hutton
Barclays
Guggenheim
1calculated from analyst ratings
Analyst Ratings for Adaptimmune Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/30/2024 | Buy Now | 160.33% | Scotiabank | George Farmer | → $3.15 | Initiates | → Sector Outperform | Get Alert |
| 05/17/2024 | Buy Now | 147.93% | Mizuho | Graig Suvannavejh | $9 → $3 | Maintains | Buy | Get Alert |
| 08/10/2023 | Buy Now | 726.45% | EF Hutton | Tony Butler | → $10 | Reiterates | Buy → Buy | Get Alert |
| 08/10/2023 | Buy Now | -17.36% | Barclays | Peter Lawson | $2 → $1 | Maintains | Underweight | Get Alert |
| 06/05/2023 | Buy Now | 726.45% | EF Hutton | Tony Butler | → $10 | Reiterates | Buy → Buy | Get Alert |
| 06/02/2023 | Buy Now | 726.45% | EF Hutton | Tony Butler | → $10 | Reiterates | → Buy | Get Alert |
| 05/26/2023 | Buy Now | 726.45% | EF Hutton | Tony Butler | → $10 | Reiterates | → Buy | Get Alert |
| 04/17/2023 | Buy Now | 726.45% | EF Hutton | Tony Butler | → $10 | Reiterates | → Buy | Get Alert |
| 04/11/2023 | Buy Now | 726.45% | EF Hutton | Tony Butler | → $10 | Reiterates | → Buy | Get Alert |
| 03/06/2023 | Buy Now | 726.45% | EF Hutton | Tony Butler | → $10 | Reiterates | → Buy | Get Alert |
| 01/05/2023 | Buy Now | 726.45% | EF Hutton | Tony Butler | → $10 | Initiates | → Buy | Get Alert |
| 01/03/2023 | Buy Now | 313.22% | Guggenheim | Michael Schmidt | → $5 | Upgrade | Neutral → Buy | Get Alert |
| 11/14/2022 | Buy Now | 147.93% | Wells Fargo | Yanan Zhu | $1.5 → $3 | Maintains | Equal-Weight | Get Alert |
| 11/09/2022 | Buy Now | 643.8% | Mizuho | Mara Goldstein | → $9 | Upgrade | Neutral → Buy | Get Alert |
| 10/04/2022 | Buy Now | 23.97% | Wells Fargo | Nick Abbott | $7 → $1.5 | Maintains | Equal-Weight | Get Alert |
| 05/09/2022 | Buy Now | 147.93% | SVB Leerink | Jonathan Chang | $2 → $3 | Maintains | Market Perform | Get Alert |
| 03/15/2022 | Buy Now | 147.93% | SVB Leerink | Jonathan Chang | $7 → $3 | Maintains | Market Perform | Get Alert |
| 09/22/2021 | Buy Now | 478.51% | Wells Fargo | — | — | Maintains | Equal-Weight | Get Alert |
| 09/13/2021 | Buy Now | 478.51% | SVB Leerink | Jonathan Chang | — | Maintains | Market Perform | Get Alert |
| 09/07/2021 | Buy Now | 395.87% | SVB Leerink | Jonathan Chang | — | Maintains | Market Perform | Get Alert |
| 08/10/2021 | Buy Now | 313.22% | SVB Leerink | Jonathan Chang | — | Maintains | Market Perform | Get Alert |
FAQ
What is the target price for Adaptimmune Therapeutics (ADAP) stock?
The latest price target for Adaptimmune Therapeutics (NASDAQ:ADAP) was reported by Scotiabank on May 30, 2024. The analyst firm set a price target for $3.15 expecting ADAP to rise to within 12 months (a possible 160.33% upside). 4 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Adaptimmune Therapeutics (ADAP)?
The latest analyst rating for Adaptimmune Therapeutics (NASDAQ:ADAP) was provided by Scotiabank, and Adaptimmune Therapeutics initiated their sector outperform rating.
When was the last upgrade for Adaptimmune Therapeutics (ADAP)?
The last upgrade for Adaptimmune Therapeutics PLC happened on January 3, 2023 when Guggenheim raised their price target to $5. Guggenheim previously had a neutral for Adaptimmune Therapeutics PLC.
When was the last downgrade for Adaptimmune Therapeutics (ADAP)?
There is no last downgrade for Adaptimmune Therapeutics.
When is the next analyst rating going to be posted or updated for Adaptimmune Therapeutics (ADAP)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Adaptimmune Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Adaptimmune Therapeutics was filed on May 30, 2024 so you should expect the next rating to be made available sometime around May 30, 2025.
Is the Analyst Rating Adaptimmune Therapeutics (ADAP) correct?
While ratings are subjective and will change, the latest Adaptimmune Therapeutics (ADAP) rating was a initiated with a price target of $0.00 to $3.15. The current price Adaptimmune Therapeutics (ADAP) is trading at is $1.21, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.